Arbutus Biopharma Corporation
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Find out what a historical investment in Arbutus Biopharma Corporation would be worth today using our ABUS stock calculator.
$629.97M
-
0.00%
536.89K
$3.35
$3.26
$3.30
$4.73
$2.63
Ready to start your investing journey with Stake?
Open an accountABUS FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in ABUS
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in ABUS
on Stake
Buy ABUS from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of ABUS from only US$10 with fractional shares
